MedPath

Actual Use Trial of Atorvastatin Calcium 10 mg

Phase 3
Completed
Conditions
Hypercholesterolemia
Interventions
Registration Number
NCT01964326
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Brief Summary

The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1311
Inclusion Criteria
  • At least 18 years of age (19 in Alabama).
  • Provide written informed consent.
  • Never participated in a study about cholesterol medicines.
Exclusion Criteria
  • Females subjects who are pregnant or breastfeeding.
  • Subjects with active liver disease.
  • Subjects taking cyclosporine.
  • Subjects with a known allergy to atorvastatin calcium.

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Atorvastatin calcium 10 mgAtorvastatin calcium 10 mg-
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) LevelDay 1 up to Week 26

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants had their LDL-C checked between Weeks 4 and 12. The behavior was considered acceptable if participants had their LDL-C checked between Weeks 2 and 3 (before Week 4) or between Weeks 13 (after Week 12) and 26 or if participants were instructed by a physician that an LDL-C test was not needed.

Percentage of Participants Who Took Appropriate Action Based on Their LDL-C ResultsDay 1 up to Week 26

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants self-reported an LDL-C level below 130 milligram per deciliter (mg/dL) or normal, or low and decided to continue with atorvastatin OTC or if participants self-reported an LDL-C below 130 mg/dL, or normal, or low but stopped the use because of new conditions preventing them from continuing use. The behavior was considered acceptable if participants self-report LDL-C level between 130 and 135 mg/dL and continued to use atorvastatin OTC without contacting a physician or other health care practitioner or if participants self-reported LDL-C greater than or equal to (\>=) 130 mg/dL('borderline high' or 'high' LDL-C), and contacted a physician after getting the LDL-C test results.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Taking an "Ask a Doctor or Pharmacist Before Use" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study MedicationDay 1 up to Week 26

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. 'Ask a doctor or pharmacist before use' medication included human immunodeficiency virus (HIV) medicine, digoxin, telaprevir, rifampin, colchicine, or oral contraceptives. The behavior of the participants was considered correct if participants asked a doctor or pharmacist before use. The behavior was considered acceptable if participants contacted a doctor or pharmacist within 7 days of initiating therapy.

Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled "Stop Use and Ask a Doctor" SymptomsDay 1 up to Week 26

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The "Stop use and ask a doctor" symptoms included: (a) unexplained muscle pain or weakness or tenderness, (b) unusual fatigue, (c) loss of appetite (d) upper belly pain (e) dark-colored urine or (f) yellowing of the whites of eyes or skin. The behavior of the participants was considered correct if participants stopped use and contacted a doctor within 7 days after the event (symptom development).The behavior was considered acceptable if participants either stopped use or contacted a doctor (but did not do both) within the 7 days' timeframe.

Trial Locations

Locations (36)

Robert's Discount Pharmacy

🇺🇸

Hoover, Alabama, United States

Pharmacy at the Pig

🇺🇸

McCalla, Alabama, United States

Pinson Discount Drugs

🇺🇸

Pinson, Alabama, United States

Community Clinical Pharmacy

🇺🇸

Mesa, Arizona, United States

Melrose Pharmacy

🇺🇸

Phoenix, Arizona, United States

Bi-Rite Quality Pharmacies

🇺🇸

La Habra, California, United States

Parkview Compounding Pharmacy

🇺🇸

Rancho Cucamonga, California, United States

Garden Drug

🇺🇸

Fort Lauderdale, Florida, United States

Pill Box Pharmacy and Medical Supply

🇺🇸

Pembroke Pines, Florida, United States

Summerfield Pharmacy

🇺🇸

Riverview, Florida, United States

Scroll for more (26 remaining)
Robert's Discount Pharmacy
🇺🇸Hoover, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.